SLC5A2 and hydrops fetalis: HF management stems from the use of highly cost-effective angiotensin converting enzyme inhibitors (ACEi) and β-blockers (BB) to the use of newer drugs such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor neprilysin inhibitor (ARNi), ivabradine, vericiguat, and omecamtiv.